BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jentzsch V, Davis JAA, Djamgoz MBA. Pancreatic Cancer (PDAC): Introduction of Evidence-Based Complementary Measures into Integrative Clinical Management. Cancers (Basel) 2020;12:E3096. [PMID: 33114159 DOI: 10.3390/cancers12113096] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Liot S, Balas J, Aubert A, Prigent L, Mercier-Gouy P, Verrier B, Bertolino P, Hennino A, Valcourt U, Lambert E. Stroma Involvement in Pancreatic Ductal Adenocarcinoma: An Overview Focusing on Extracellular Matrix Proteins. Front Immunol 2021;12:612271. [PMID: 33889150 DOI: 10.3389/fimmu.2021.612271] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
2 Tang P, Qu W, Wu D, Chen S, Liu M, Chen W, Ai Q, Tang H, Zhou H. Identifying and Validating an Acidosis-Related Signature Associated with Prognosis and Tumor Immune Infiltration Characteristics in Pancreatic Carcinoma. J Immunol Res 2021;2021:3821055. [PMID: 34993253 DOI: 10.1155/2021/3821055] [Reference Citation Analysis]
3 Chiang NJ, Chen LT, Shan YS, Yeh CN, Chen MH. Development of Possible Next Line of Systemic Therapies for Gemcitabine-Resistant Biliary Tract Cancers: A Perspective from Clinical Trials. Biomolecules 2021;11:97. [PMID: 33451059 DOI: 10.3390/biom11010097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Moballegh Nasery M, Varzandeh M, Pahlavanneshan S, Mohamadi N, Sarhadi S, Samareh Fekri H, Mohammadinejad R, Ahn KS. Curcumin: A potential therapeutic natural product for adenocarcinomas. Phytochemistry Letters 2022;49:45-55. [DOI: 10.1016/j.phytol.2022.02.013] [Reference Citation Analysis]
5 Fan G, Lou L, Song Z, Zhang X, Xiong XF. Targeting mutated GTPase KRAS in tumor therapies. Eur J Med Chem 2021;226:113816. [PMID: 34520956 DOI: 10.1016/j.ejmech.2021.113816] [Reference Citation Analysis]
6 Natesh NS, White BM, Bennett MMC, Uz M, Kalari Kandy RR, Batra SK, Mallapragada SK, Rachagani S. Emerging Role of miR-345 and Its Effective Delivery as a Potential Therapeutic Candidate in Pancreatic Cancer and Other Cancers. Pharmaceutics 2021;13:1987. [PMID: 34959269 DOI: 10.3390/pharmaceutics13121987] [Reference Citation Analysis]
7 Huang H, Li H, Pan R, Wang S, Liu X. tRNA modifications and their potential roles in pancreatic cancer. Arch Biochem Biophys 2021;714:109083. [PMID: 34785212 DOI: 10.1016/j.abb.2021.109083] [Reference Citation Analysis]
8 Djamgoz MBA, Jentzsch V. Integrative Management of Pancreatic Cancer (PDAC): Emerging Complementary Agents and Modalities. Nutr Cancer 2021;:1-24. [PMID: 34085871 DOI: 10.1080/01635581.2021.1934043] [Reference Citation Analysis]